
Matthew S. Davids, MD, MMSc, discusses key efficacy results from 2 follow-up analyses of the phase 1/2 BRUIN trial evaluating pirtobrutinib.

Your AI-Trained Oncology Knowledge Connection!


Matthew S. Davids, MD, MMSc, discusses key efficacy results from 2 follow-up analyses of the phase 1/2 BRUIN trial evaluating pirtobrutinib.

Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.

Shared insight on updates in the chronic myeloid leukemia treatment landscape following the ASH 2021 annual meeting.

Expert perspectives on clinical data readouts in acute lymphocytic leukemia from the ASH 2021 annual meeting.






Published: December 23rd 2020 | Updated:

Published: January 18th 2021 | Updated:

Published: January 31st 2022 | Updated:

Published: January 22nd 2021 | Updated:

Published: January 22nd 2021 | Updated:

Published: January 22nd 2021 | Updated: